The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [¹⁷⁷Lu]Lu-PSMA-I&T for triple-negative breast cancer.

ABSTRACT:

Introduction

Overexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [¹⁷⁷Lu]Lu-PSMA-I&T. This study aimed to assess and compare the therapeutic efficacy of a single dose with a fractionated dose of [¹⁷⁷Lu]Lu-PSMA-I&T in an orthotopic model of TNBC.

Methods

Rj:NMRI-Foxn1^nu/nu mice were used as recipients of MDA-MB-231 xenografts. The single dose group was treated with 1 × 60 ± 5 MBq dose of [¹⁷⁷Lu]Lu-PSMA-I&T, while the fractionated dose group received 4 × a 15 ± 2 MBq dose of [¹⁷⁷Lu]Lu-PSMA-I&T at 7 day intervals. The control group received 0.9% NaCl. Tumor progression was monitored using [

SUBMITTER: Heesch A 

PROVIDER: S-EPMC10877802 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature